Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: a phase II study.

摘要: BACKGROUND Cancer in the elderly is becoming a complex and frequent issue. At least 30% of lung carcinomas are expected to arise each year patients, who often have significant comorbidity. The most appropriate treatment for this large portion cancer patients remains unknown. purpose Phase II trial was make comprehensive evaluation activity, toxicity, tolerability single-agent vinorelbine relatively poorly performing with inoperable nonsmall cell carcinoma (NSCLC). METHODS Patients age 70 years or older were eligible participate if they had pathologic diagnosis, performance status lower than 4 (Eastern Cooperative Oncology Group [ECOG] scale), gave informed consent. Vinorelbine given intravenously (i.v.) at dose 25 mg/m2 every week until progression, persistent refusal. RESULTS Forty-six entered study; their median 75 (range, 70–83 years). Five never started on vinorelbine; 27 others early suspensions. number weekly infusions 5 0–28); intensity 70% projected. Toxicity generally mild, mainly hematologic, life-threatening. ECOG status, body weight, almost all scores from quality-of-life questionnaires remained constant during first 6 weeks treatment. Two obtained partial response, 10 some tumor regression, 26 stabilization. estimated time progression 19 (quartile range, 11–23 weeks), survival 34 16–63 weeks). CONCLUSIONS In our group poor prognoses, well tolerated, moderately active, capable ensuring long survival. It may represent valuable therapeutic option nonresectable NSCLC patients. Cancer 2000;88:2677–85. © 2000 American Society.